{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:55:22Z","timestamp":1794185722967,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005413","name":"Universit\u00e9 Paris Descartes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002738","name":"Assistance Publique - H\u00f4pitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.phrs.2017.07.026","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T07:32:50Z","timestamp":1501659170000},"page":"116-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":282,"special_numbering":"C","title":["Antihypertensive drugs"],"prefix":"10.1016","volume":"124","author":[{"given":"St\u00e9phane","family":"Laurent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.07.026_bib0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/HYPERTENSIONAHA.111.177766","article-title":"Historical trends and milestones in hypertension research: a model of the process of translational research","volume":"58","author":"Kotchen","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0010","series-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"780","article-title":"Antihypertensive agents and the drug therapy of hypertension","author":"Oates","year":"1995"},{"key":"10.1016\/j.phrs.2017.07.026_bib0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00003088-200241070-00004","article-title":"Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines","volume":"41","author":"Frishman","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2017.07.026_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2012.159","article-title":"Coronary artery disease: Are \u03b2-blockers truly helpful in patients with CAD?","volume":"10","author":"Danchin","year":"2012","journal-title":"Nat. Rev. Cardiol."},{"issue":"12 Pt 1","key":"10.1016\/j.phrs.2017.07.026_bib0025","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.amjhyper.2004.05.023","article-title":"Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment","volume":"17","author":"Schiffrin","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2017.07.026_bib0030","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2165\/11593790-000000000-00000","article-title":"Pharmacological modulation of arterial stiffness","volume":"71","author":"Boutouyrie","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2017.07.026_bib0035","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/HYPERTENSIONAHA.109.148999","article-title":"EXPLOR Trialist Group: amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study","volume":"55","author":"Boutouyrie","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0040","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0140-6736(10)60960-9","article-title":"Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial","volume":"376","author":"Ong","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.07.026_bib0045","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.07.026_bib0050","series-title":"Hypertension, a Companion to Braunwald\u2019s Heart Disease","first-page":"231","article-title":"Angiotensin receptor blockers","author":"Frishman","year":"2007"},{"key":"10.1016\/j.phrs.2017.07.026_bib0055","series-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"685","article-title":"Diuretics","author":"Jackson","year":"1995"},{"key":"10.1016\/j.phrs.2017.07.026_bib0060","series-title":"Hypertension, a Companion to Braunwald\u2019s Heart Disease","first-page":"213","article-title":"Diuretic therapy in cardiovascular disease","author":"Sica","year":"2007"},{"key":"10.1016\/j.phrs.2017.07.026_bib0065","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/bdd.2510070602","article-title":"Pharmacokinetics of the thiazide diuretics","volume":"7","author":"Welling","year":"1986","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.phrs.2017.07.026_bib0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3317\/jraas.2004.034","article-title":"How do thiazide and thiazide-like diuretics lower blood pressure","volume":"5","author":"Hughes","year":"2004","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.phrs.2017.07.026_bib0075","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM197104152841506","article-title":"Thiazide-induced hypercalcemia","volume":"284","author":"Duarte","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.07.026_bib0080","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","article-title":"Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension","volume":"93","author":"Williams","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.07.026_sbref0085a","series-title":"Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"733","article-title":"Renin and angiotensin","author":"Jackson","year":"1995"},{"key":"10.1016\/j.phrs.2017.07.026_sbref0085b","series-title":"Cochrane Database Syst. Rev.","first-page":"CD004934","article-title":"Hydralazine for essential hypertension","author":"Jackson","year":"2010"},{"key":"10.1016\/j.phrs.2017.07.026_bib0090","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0735-1097(01)01111-1","article-title":"Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease","volume":"37","author":"Petrie","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2017.07.026_bib0095","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.113.01274","article-title":"Angiotensin-(1\u20137)","volume":"63","author":"Santos","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0100","first-page":"80","article-title":"Pfeffer MA; Prevention of Events with Angiotensin-Converting Enzyme Inhibition Investigators. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin converting enzyme inhibition","volume":"48","author":"Mitchell","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/01.HYP.0000224283.76347.8c","article-title":"Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives","volume":"48","author":"Tropeano","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0110","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1097\/HJH.0b013e328329272e","article-title":"Effects of antihypertensive treatment on small artery remodelling","volume":"27","author":"Agabiti-Rosei","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.07.026_bib0115","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.07.026_bib0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.07.026_bib0125","series-title":"Hypertension, a Companion to Braunwald\u2019s Heart Disease","first-page":"239","article-title":"Angiotensin-converting enzyme inhibitors","author":"Sica","year":"2007"},{"key":"10.1016\/j.phrs.2017.07.026_bib0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.phrs.2017.07.026_bib0135","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/HYPERTENSIONAHA.114.03282","article-title":"Vascular mechanism collaboration: dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome","volume":"64","author":"Laurent","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1291\/hypres.28.937","article-title":"Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients","volume":"28","author":"Nakamura","year":"2005","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.phrs.2017.07.026_bib0145","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","article-title":"Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease","volume":"106","author":"Edwards","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2017.07.026_bib0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2017.07.026_bib0155","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00007890-200108150-00035","article-title":"Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study","volume":"72","author":"Yildiz","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.phrs.2017.07.026_bib0160","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2017.07.026_bib0165","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00041552-200109000-00011","article-title":"Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy","volume":"10","author":"Schiffrin","year":"2001","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.phrs.2017.07.026_bib0170","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.07.026_bib0175","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2017.07.026_bib0180","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group: angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.07.026_bib0185","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"ONTARGET investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.07.026_bib0190","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2165\/00003495-199651050-00007","article-title":"Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease","volume":"51","author":"Brogden","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2017.07.026_bib0195","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2165\/00003495-199550030-00009","article-title":"Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease","volume":"50","author":"Haria","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2017.07.026_bib0200","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00500899","article-title":"Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium","volume":"298","author":"Kohlhardt","year":"1977","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.phrs.2017.07.026_bib0205","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/01.RES.55.3.336","article-title":"Voltage-dependent block of calcium channel current in the calf cardiac Purkinje fiber by dihydropyridine calcium channel antagonists","volume":"55","author":"Sanguinetti","year":"1984","journal-title":"Circ. Res."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2017.07.026_bib0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/08037051.2012.690615","article-title":"Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS","volume":"21","author":"Toal","year":"2012","journal-title":"Blood Press."},{"key":"10.1016\/j.phrs.2017.07.026_bib0215","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0735-1097(97)00095-8","article-title":"Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics","volume":"29","author":"Wenzel","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2017.07.026_bib0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.HYP.24.3.287","article-title":"Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension","volume":"24","author":"Lindqvist","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0225","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.HYP.0000058003.27729.5A","article-title":"Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension","volume":"41","author":"Grassi","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0230","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2165\/00003495-199039050-00009","article-title":"Diltiazem. A reappraisal of its pharmacological properties and therapeutic use","volume":"39","author":"Buckley","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2017.07.026_bib0235","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/archinte.1992.00400200011003","article-title":"Calcium antagonists and renal protection: current status and future perspectives","volume":"152","author":"Epstein","year":"1992","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2017.07.026_bib0240","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2165\/00003495-200161120-00010","article-title":"Manidipine: a review of its use in hypertension","volume":"61","author":"Cheer","year":"2001","journal-title":"Drugs"},{"issue":"Suppl, 2","key":"10.1016\/j.phrs.2017.07.026_bib0245","first-page":"1","article-title":"Vascular effects of calcium channel antagonists: new evidence","volume":"65","author":"Richard","year":"2005","journal-title":"Drugs"},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2017.07.026_bib0250","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003495-200565002-00004","article-title":"Ankle oedema and sympathetic activation","volume":"65","author":"Fogari","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2017.07.026_bib0255","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-199615020-00002","article-title":"A comparative review of the adverse effects of calcium antagonists","volume":"15","author":"Dougall","year":"1996","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2017.07.026_bib0260","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1074-5521(00)00134-4","article-title":"Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin","volume":"7","author":"Rahuel","year":"2000","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2017.07.026_bib0265","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1161\/HYPERTENSIONAHA.108.109967","article-title":"The renin rise with aliskiren: it\u2019s simply stoichiometry","volume":"51","author":"Danser","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2017.07.026_bib0270","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"35","key":"10.1016\/j.phrs.2017.07.026_bib0275","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/eurheartj\/ehu079","article-title":"Aliskiren prevention of later life lutcomes trial Investigators. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial","volume":"201","author":"Teo","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2017.07.026_bib0280","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/00004872-198900076-00023","article-title":"Central haemodynamics in essential hypertension at rest and during exercise: a 20-year follow-up study","volume":"7","author":"Lund-Johansen","year":"1989","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.phrs.2017.07.026_bib0285","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/08038020310000078","article-title":"Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies","volume":"1","author":"Lund-Johansen","year":"2003","journal-title":"Blood Press. Suppl."},{"key":"10.1016\/j.phrs.2017.07.026_bib0290","first-page":"40","article-title":"Action of \u2212adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine","volume":"23","author":"Schmitt","year":"1973","journal-title":"Arzneimittelforschung"},{"issue":"4 Pt 2","key":"10.1016\/j.phrs.2017.07.026_bib0295","doi-asserted-by":"crossref","first-page":"47S","DOI":"10.1093\/ajh\/5.4.47S","article-title":"Imidazoline receptors: a new concept in central regulation of the arterial blood pressure","volume":"5","author":"Bousquet","year":"1992","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2017.07.026_bib0300","doi-asserted-by":"crossref","first-page":"99S","DOI":"10.1093\/ajh\/5.4.99S","article-title":"Rilmenidine: a novel approach to first-line treatment of hypertension","volume":"5","author":"Laurent","year":"1992","journal-title":"Am. J Hypertens."},{"key":"10.1016\/j.phrs.2017.07.026_bib0305","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003495-198122040-00001","article-title":"Minoxidil: a review of its pharmacological properties and therapeutic use","volume":"22","author":"Campese","year":"1981","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2017.07.026_bib0310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/med.10060","article-title":"KATP channel openers: structure-activity relationships and therapeutic potential","volume":"24","author":"Mannhold","year":"2004","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2017.07.026_bib0315","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0163-7258(90)90082-D","article-title":"Potassium channel openers and vascular smooth muscle relaxation","volume":"48","author":"Edwards","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2017.07.026_bib0320","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/01.ccx.0000145099.20822.19","article-title":"ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction","volume":"10","author":"Pollesello","year":"2004","journal-title":"Curr. Opin. Crit. Care"},{"issue":"suppl 2","key":"10.1016\/j.phrs.2017.07.026_bib0325","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1097\/00005344-198000022-00015","article-title":"Treatment of drug resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, aldosterone, and electrolyte responses","volume":"2","author":"Baer","year":"1980","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2017.07.026_bib0330","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0140-6736(92)92141-2","article-title":"Hair loss with minoxidil withdrawal","volume":"340","author":"Kidwai","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2017.07.026_bib0335","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1056\/NEJM197003052821001","article-title":"Treatment of essential hypertension with a new vasodilator in combination with betaadrenergic blockade","volume":"282","author":"Gilmore","year":"1970","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2017.07.026_bib0340","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1751-7176.2011.00507.x","article-title":"Direct-acting vasodilators","volume":"13","author":"Cohn","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)."},{"key":"10.1016\/j.phrs.2017.07.026_bib0345","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2017.07.026_bib0350","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mob.2000.107928","article-title":"Report of the national high blood pressure education program working group on high blood pressure in pregnancy","volume":"183","year":"2000","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.phrs.2017.07.026_bib0355","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/HYPERTENSIONAHA.106.075895","article-title":"Update on the use of antihypertensive drugs in pregnancy","volume":"51","author":"Podymow","year":"2008","journal-title":"Hypertension"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817308460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817308460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:44:25Z","timestamp":1657241065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817308460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":72,"alternative-id":["S1043661817308460"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.07.026","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antihypertensive drugs","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}